Clinical Trial Search

Primary: Percentage of Participants With Generalized Pustular Psoriasis (GPP) Achieving GPP Clinical Response at Week 16 — 100; 100 percentage of participants

Primary: Changes in Insulin-like Growth Factor-1 (IGF-1), IGF Binding Proteins (IGFBP-1, IGFBP-3), and Acid Labile Subunit (ALS) — 220.6; 228.7; 197.1; 221.4 ng/mL

Primary: Area Under the Curve of Deferasirox After a Dose of 35 mg/kg — 479.59; 1123.11 micromole/liter*hour — p=<.001

Primary: Number of Participants With Target Lesion Failure (TLF) — 11; 5 Participants

Primary: Percentage of Participants With Immediate Reactions — 0; 0; 28; 10 Participants

Primary: Overall Survival and Progression Free Survival — 29; 12.9; 22 percentage of participants

Primary: Change in Buccal Plate Thickness From Baseline to Month 6 — 1.85; 1.25 mm — p=0.11

Primary: Percentage of Participants With Treatment-Emergent (TE) Adverse Events (AE), Serious AEs (SAE), AEs Leading to Premature Study Drug Discontinuation, and Grade 3 or 4…

Primary: Number of Participants With Adverse Events — 0; 1; 3; 3 Participants

Primary: Area Under the Curve for Amlodipine in the Maternal Serum — 53.4 (hr*ng)/mL

Primary: Mean Change From Baseline in Daily, Reflective Total Nasal Symptom Scores (rTNSS) Over the First 2 Weeks Treatment Period — -1.95; -3.18; -3.28 Scores on a scale…

Primary: Incidence of Adverse Events — 19; 18 participants

Primary: Change in 24 Hour Creatinine Clearance — 41.0 mL/min/SA — p=0.072

Primary: Incidence of Adverse Events — 8; 7 participants

Primary: Overall Survival (OS) — 23.82; 22.21 months — p== 0.5236